PCRX Pacira BioSciences margins

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCRX
  4. Margins
?
Relative Growth: Rel. Growth: 71
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 49
Relative Profitability: Rel. Profitability: 62
Gross margin
79.2%
Operating margin
2.7%
EBITDA margin
15.9%
Net margin
2%

Based on the latest figures, Pacira BioSciences reports a gross margin of 79.2%, an operating margin of 2.7%, an EBITDA margin of 15.9%, and a net margin of 2%. The company's available margins all advanced, with net margin reporting the strongest expansion of 20.1 percentage points.

PCRX margin history

Gross, operating, EBITDA and net margin trends

Looking back over the last 3 years, Pacira BioSciences recorded average margins of 76.62% gross, 0.86% operating, 14.91% EBITDA, and -2.53% net. Compared with their three-year averages, all four current margins are higher.

PCRX margin expansion

Year-over-year margin changes in percentage points

Gross margin expanded by 1 percentage point, operating margin by 17.5 percentage points, EBITDA margin by 15.6 percentage points, and net margin by 20.1 percentage points, led by net margin with an increase of 20.1 percentage points.

Gross margin expansion
1pp
Operating margin expansion
17.5pp
EBITDA margin expansion
15.6pp
Net margin expansion
20.1pp

PCRX Gross margin

Over the last 3 years, the average gross margin for Pacira BioSciences was 76.62%. Against its three-year average, Pacira BioSciences's gross margin is currently 79.2%, 2.6 percentage points above its three-year average. Pacira BioSciences's gross margin ranged from a low of 72.6% in Dec 2023 to a high of 79.4% in Dec 2025.

PCRX Operating margin

The average operating margin for Pacira BioSciences was 0.86% over the last 3 years. As of the latest period, the current operating margin for Pacira BioSciences is 2.7%, 1.8 percentage points above its three-year average. The operating margin for Pacira BioSciences moved between -14.8% in Jun 2025 and 15.3% in Mar 2024.

PCRX EBITDA margin

Across the last 3 years, Pacira BioSciences recorded an average EBITDA margin of 14.91%. Against its three-year average, Pacira BioSciences's EBITDA margin is currently 15.9%, 1 percentage points above its three-year average. The highest EBITDA margin for Pacira BioSciences was 27.9% in Mar 2024, while the lowest was 0.3% in Jun 2025.

PCRX Net margin

Reviewing the last 3 years, Pacira BioSciences recorded an average net margin of -2.53%. Pacira BioSciences's current net margin is 2% and is 4.5 percentage points above its three-year average. The highest net margin for Pacira BioSciences was 10.3% in Mar 2024, while the lowest was -18.1% in Jun 2025.

PCRX margin group comparison

Margins compared with peer-group, industry and sector averages

Pacira BioSciences's gross margin of 79.2% is higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.3%, Pacira BioSciences's gross margin is 16% higher.

PCRX margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Pacira BioSciences's gross margin?

The current gross margin for PCRX is 79.2% as of Jun 30, 2026.

What is Pacira BioSciences's operating margin?

For the period ending Jun 30, 2026, PCRX recorded an operating margin of 2.7%.

What is Pacira BioSciences's EBITDA margin?

For the period ending Jun 30, 2026, PCRX recorded an EBITDA margin of 15.9%.

What is Pacira BioSciences's net margin?

For the period ending Jun 30, 2026, PCRX recorded a net margin of 2%.

What are the average margins of PCRX?

Pacira BioSciences's average margins over the last 3 years were 76.6% gross, 0.9% operating, 14.9% EBITDA, and -2.5% net.

What are the highest historical margins of PCRX?

Within the 5-year period, PCRX recorded its highest margins at 79.4% gross in Dec 2025, 16.6% operating in Dec 2021, 27.9% EBITDA in Mar 2024, and 10.3% net in Mar 2024.

What are the lowest historical margins of PCRX?

Over this 5-year history, Pacira BioSciences's margins fell as low as 68.3% gross in Mar 2023, -14.8% operating in Jun 2025, 0.3% EBITDA in Jun 2025, and -18.1% net in Jun 2025.